A trial looking at everolimus for neuroendocrine tumours (RADIANT 4)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Neuroendocrine tumour (NET)




Phase 3

This trial is looking at everolimus (Afinitor) to treat neuroendocrine tumours (NETs) of the digestive system or lungs.

Neuroendocrine tumours (NETs) are a rare group of cancers that develop in the neuroendocrine system. Some make extra hormones Open a glossary item and cause symptoms, and others don’t. This trial is is for people who have a NET of the digestive system Open a glossary item or lungs that does not make extra hormones.

Doctors can help control the growth and improve the symptoms of NETs with

Everolimus is a biological therapy. It works by stopping a protein called mTOR from working properly. mTOR controls other proteins that trigger cancer cells to grow. So by blocking it, everolimus helps to stop the cancer growing. We know from research that everolimus may help treat NETs.

The aim of this trial is to find out if everolimus can help people with non functioning NETs of the digestive system or lungs.

Who can enter

You may be able to enter this trial if

  • You have a non functioning neuroendocrine tumour (NF-NET) of the digestive system or lungs
  • Your tumour cannot be removed with surgery, has spread to another part of your body or has continued to grow during or after treatment
  • You have had a scan that shows your tumour has grown in the past 6 months
  • Your tumour can be measured on a scan
  • You have satisfactory blood test results
  • You are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
  • You are willing to use reliable contraception during treatment if there is any chance you or your partner could become pregnant
  • You are at least 18 years old

You cannot enter this trial if you

  • Have carcinoid syndrome
  • Have had a somatostatin analogue, interferon or  chemotherapy in the past month
  • Have had a radiolabelled somatostatin analogue in the past 6 months
  • Have had more than 1 course of chemotherapy
  • Have already had another biological therapy
  • Have had treatment aimed at blocking blood vessels in your liver (hepatic artery embolisation) in the past 6 months
  • Have had your tumour treated by freezing it (cryoablation or cryotherapy) or heating it with radiowaves (radiofrequency ablation) in the past 2 months
  • Have already had everolimus or a similar drug such as sirolimus, temsirolimus or deforolimus
  • Are known to be sensitive to everolimus or similar drugs and their ingredients
  • Are having ongoing treatment with steroids or any other drug that can suppress your immune system Open a glossary item
  • Have had an experimental drug as part of another clinical trial in the past month
  • Have diabetes that is not well controlled
  • Have had a heart attack in the past 6 months or any other serious heart problem
  • Have an infection
  • Have a problem with your liver such as cirrhosis
  • Have severe breathing problems
  • Have bleeding problems
  • Have any condition where your body cannot properly absorb tablets
  • Are known to be HIV, hepatitis B or hepatitis C positive
  • Have had another cancer apart from non melanoma skin cancer, carcinoma in situ Open a glossary item of the cervix, womb (uterus) or breast that has been successfully treated and there has been no sign of disease for at least 3 years
  • Have had a live vaccine Open a glossary item such as the flu vaccine in the past week
  • Have any other medical condition that could affect you taking part in this trial
  • Are pregnant or breastfeeding

Trial design

This is a phase 3 international trial. It will recruit 285 people from different countries around the world. This is a randomised trial. The people taking part are put into treatment groups by a computer. Neither you nor your doctor will be able to decide which group you are in. And neither of you will know which group you are in either. This is called a double blind trial.

People in group 1 have everolimus. People in group 2 have a dummy drug (placebo). Both everolimus and the dummy drug are tablets. You take them once a day. You continue taking them as long as they are helping you and the side effects aren’t too bad.

The trial team will ask you to fill out 2 questionnaires before you start treatment, every 2 months for a year and then every 3 months. The questionnaire will ask about side effects and how you’ve been feeling. This is called a quality of life study.

If you agree to take part in this study, the researchers will also ask for a sample of tissue taken from when you had your biopsy or surgery to remove your tumour.

Hospital visits

You will see the doctor and have some tests before taking part in this trial. These tests include

  • A physical examination
  • Blood tests
  • Heart trace (ECG Open a glossary item)
  • CT scan or MRI scan
  • Urine test

During treatment you see the doctor every month for a physical examination, blood and urine tests.

After treatment your doctor will see you in clinic or contact you every 3 months to see how you are.

Side effects

The most common side effects of everolimus are

We have more information on everolimus in our cancer drugs section.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Juan Valle

Supported by

Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 9478

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page